APTORUM GROUP LIMITED

(APM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Aptorum Group 30% Higher Premarket After FDA Orphan Drug Designation

01/20/2022 | 08:56am EDT

By Michael Dabaie


Aptorum Group Ltd. shares rose 30%, to $1.59, premarket after the clinical-stage biopharmaceutical company said the U.S. Food and Drug Administration granted orphan drug designation to SACT-1.

The designation is for the treatment of patients with neuroblastoma. Neuroblastoma is one of the most prevailing solid tumor cancers in children, representing 8% to 10% of all childhood tumors, the company said.

Aptorum Group plans to file an investigational new drug application to begin a phase 1b/2a clinical trial for SACT-1 to test the drug in neuroblastoma patients in 2022.


Write to Michael Dabaie at michael.dabaie@wsj.com


(END) Dow Jones Newswires

01-20-22 0856ET

All news about APTORUM GROUP LIMITED
08:22aAptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, M..
BU
05/02Aptorum Says Rare Cancer Drug Well Tolerated in Early-Stage Study
MT
05/02Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targ..
BU
05/02Aptorum Group Limited Updates on Data from Completed Phase 1 Clinical Trial of SACT-1, ..
CI
04/29APTORUM : Reports 2021 Fiscal Year End Financial Results and Provides Business Update - Fo..
PU
04/29Aptorum Group Limited Reports Earnings Results for the Full Year Ended December 31, 202..
CI
04/29Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Busin..
BU
04/29APTORUM GROUP LIMITED : Annual results
CO
04/29APTORUM GROUP LIMITED : SEC Filing 20 F
CO
04/29APTORUM GROUP LIMITED : SEC Filing 6K-4
CO
More news
Financials (USD)
Sales 2022 1,50 M - -
Net income 2022 -35,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,11x
Yield 2022 -
Capitalization 39,6 M 39,6 M -
Capi. / Sales 2022 26,4x
Capi. / Sales 2023 20,9x
Nbr of Employees 26
Free-Float 25,4%
Chart APTORUM GROUP LIMITED
Duration : Period :
Aptorum Group Limited Technical Analysis Chart | APM | KYG6096M1069 | MarketScreener
Technical analysis trends APTORUM GROUP LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 1,11 $
Average target price 15,00 $
Spread / Average Target 1 251%
EPS Revisions
Managers and Directors
Ian Huen Director
Darren Lui President & Executive Director
Sabrina Khan Chief Financial Officer
Clark Cheng Executive Director & Chief Medical Officer
Wai-Yip Lee Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
APTORUM GROUP LIMITED-26.00%37
JOHNSON & JOHNSON4.10%468 600
PFIZER, INC.-14.19%284 304
ABBVIE INC.14.82%274 733
ELI LILLY AND COMPANY8.38%269 490
ROCHE HOLDING AG-14.96%260 807